Trials / Completed
CompletedNCT00344513
Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF): An Internet-based Registry and Process of Care Improvement Program for Heart Failure Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 50,000 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This program is designed to improve medical care and education of hospitalized patients with heart failure and accelerate the initiation of evidence-based heart failure guideline recommended therapies by administering them before hospital discharge. A registry component focusing on admission to discharge and 60- to 90-day follow-up is designed to evaluate the demographic, pathophysiologic, clinical, treatment, and outcome characteristics of patients hospitalized with heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Beta-blockers including Carvedilol | |
| DRUG | ACE inhibitors |
Timeline
- Start date
- 2002-12-16
- Completion
- 2005-06-30
- First posted
- 2006-06-26
- Last updated
- 2020-11-24
Source: ClinicalTrials.gov record NCT00344513. Inclusion in this directory is not an endorsement.